

**PRV**PATENT- OCH REGISTRERINGSVERKET  
Patentavdelningen

REC'D 09.AUG 2004

WIPO PCT

**Intyg  
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) Sökande                      AstraZeneca AB, Södertälje SE  
Applicant (s)

(21) Patentansökningsnummer    0302122-7  
Patent application number

(86) Ingivningsdatum                      2003-07-22  
Date of filing

Stockholm, 2004-06-30

För Patent- och registreringsverket  
For the Patent- and Registration Office

Hjordis Segerlund

Avgift  
Fee                      170:-

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

PATENT- OCH  
REGISTRERINGSVERKET  
SWEDEN

Postadress/Adress  
Box 5055  
S-102 42 STOCKHOLM

Telefon/Phone  
+46 8 782 25 00  
Vx 08-782 25 00

Telex  
17978  
PATOREG S

Telefax  
+46 8 666 02 86  
08-666 02 86

-1-

## FIELD OF THE INVENTION

The present invention describes a coronary artery disease susceptibility gene and its use in the diagnosis and therapy of CAD.

## BACKGROUND

Coronary artery disease (CAD) is the most common type of heart disease. It is a consequence of atherosclerosis, which is a progressive inflammatory tissue response resulting from deposition of modified lipoproteins in the arterial intima of the vascular wall. This process can lead to development of complex atherosclerotic lesions or plaques at pre-existing focal arterial intima cushions rich in extracellular matrix (Glass *et al*, Cell 104, 503-516, 2001). Overtime these lesions narrow the coronary arteries, restricting blood flow to the heart and can cause angina. Complete blockage can lead to myocardial infarction.

The known risk factors for CAD include type II diabetes, insulin resistance, obesity (Rao *et al*, Am. Heart J. 142, 1102-1107, 2001), hyperlipidemia, high blood pressure, cigarette smoking and physical inactivity. CAD is also known to have a significant genetic component.

There are no drugs currently available to prevent CAD. Efforts have been focussed at measures to slow down CAD, and different drugs and surgical techniques are available to repair clogged coronary arteries. However, there is a need for a better understanding of the pathophysiology of CAD and the development of specific and effective drugs.

To develop more effective drugs, it is critical that the susceptibility genes for CAD are identified. As mentioned above, the pathogenesis of CAD has been shown by twin and other studies to include a significant genetic component, and the effects of genes on susceptibility to CAD are likely to be particularly strong at younger ages (Marenberg *et al*, New England J Med 330, 1041-1046, 1994). However, CAD is unlikely to be inherited as a simple Mendelian trait, but is instead a complex multifactorial disorder in which the phenotype is heavily influenced by environmental as well as genetic factors. Although a number of loci have been identified for risk factors related to CAD, only a limited number of genome

-2-

scanning studies have been published showing linkage to CAD. For example, CAD has been linked to chromosome 2 and X (Pajukanta et al, Am. J. Hum. Genet. 67, 1481-1493, 2000), chromosome 16 (Francke *et al.*, Human Molec. Genet. 10, 2751-2765, 2001) and chromosome 14 (Broeckel *et al.*, Nature Genetics 30, 210, 2002).

### SUMMARY OF THE INVENTION

The present invention describes the identification of a CAD susceptibility gene, a basic helix-loop-helix transcription factor 2 (BHLHB2). The identification of BHLHB2 as a CAD susceptibility gene enables the development of novel therapies for CAD by screening for compounds and other entities, such as antibodies, which modulate the activity of BHLHB2. Knowledge of the BHLHB2 gene sequence also enables the development of novel antigene methods to modulate the expression of the associated gene and may also enable the development of novel gene therapy techniques to treat CAD. The discovery of the linkage between BHLHB2 and CAD may also assist in developing novel methods for diagnosing CAD via (i) measuring the levels of the translated mRNA of BHLHB2 present in affected tissue and (ii) measuring the levels of the BHLHB2 protein in affected tissue. It is possible that the diagnosis of CAD, or the susceptibility of an individual to CAD, by these methods may be achieved in patients who do not yet display the classical symptoms of the disease. Such determination of susceptibility to CAD, or the early detection of disease development, will lead to earlier clinical intervention than is currently possible and will lead to more effective treatment of the disease.

Specifically, the invention includes a method of identifying a test compound that modulates the expression of a BHLHB2 gene, includes contacting a cell capable of expressing a BHLHB2 gene with a test compound; and determining the level of expression of the BHLHB2 gene in the presence of the test compound, wherein a decrease or an increase in BHLHB2 gene expression, as compared to the level of expression of BHLHB2 in the absence of the compound, is indicative that the test compound modulates BHLHB2 gene expression.

-3-

Also within the invention is a method of identifying a test compound that modulates the activity of a protein encoded by the BHLHB2 gene, including contacting the protein with a test compound and determining the level of activity of the BHLHB2 protein in the presence of the compound, wherein a decrease or an increase in the protein activity, as compared to the level of activity of the BHLHB2 protein in the absence of the compound, is indicative that the test compound modulates BHLHB2 protein activity.

The invention further includes a method for determining if a BHLBH2 gene has an altered level of gene expression in a CAD cell. The method includes comparing the level of BHLBH2 gene expression in a cell from a patient having CAD with a control cell (a cell from a patient not having CAD), and determining the level of expression of the BHLBH2 gene in both cells, wherein a decrease or an increase in expression of the BHLBH2 gene, as compared to the level of expression of the BHLBH2 gene in the control cell, indicates that the BHLBH2 has altered gene expression.

15

Also within the invention is a method for determining the level of a BHLBH2 protein in a CAD patient compared to a control including comparing the protein level of BHLBH2 in a cell from a patient having CAD with a control cell (a cell from a patient not having CAD), and determining the level of the BHLBH2 protein in both cells.

20

In another aspect, the invention includes a method of identifying a binding partner of the BHLHB2 protein including contacting a BHLHB2 protein with a test target protein, and determining if the test target protein can interact with the BHLHB2 protein, wherein interaction of the test target protein with BHLBH2 indicates that the test target protein is a BHLBH2 binding partner. In one embodiment, the method can further include contacting a gene encoding the test target protein with a test compound; and determining the level of expression of the test target gene in the presence of the test compound, wherein a decrease or an increase in test target gene expression, as compared to the level of expression of the test target gene in the absence of the compound, is indicative that the test compound modulates expression of the test target gene and is useful in the treatment of CAD. In another

30

embodiment, the method further includes contacting the test target protein with a test compound; and determining the level of activity of the test target protein in the presence of the test compound, wherein a decrease or an increase in test target protein activity, as compared to the level of activity of the test target protein in the absence of the compound, is  
5 indicative that the test compound modulates test target protein activity and is useful in the treatment of CAD.

The invention further features a method of treating a subject having CAD comprising administering an effective amount of the compound identified above. The invention further  
10 includes a pharmaceutical composition comprising the compound identified as above.

In another aspect, the invention includes a method of identifying other components of the CAD biochemical pathway of which BHLHB2 is a component.

15 The invention further includes methods of diagnosing CAD or a susceptibility thereto in a subject. The method includes determining the level of a BHLHB2 protein in a sample from a subject; and comparing the level of the protein in the sample with a control, wherein a decrease or an increase in the level of the protein in the sample compared to the control indicates that the subject has CAD, or a susceptibility thereto. The invention also extends to  
20 products useful for carrying out the assay, such as DNA probes (labelled or unlabelled), kits and the like.

The present invention also includes gene-based therapies directed at the BHLHB2 gene. Therapies may be in the form of polynucleotides comprising all or a portion of the BHLHB2  
25 gene, placed in appropriate vectors or delivered to target cells in direct ways which would modify the function of the BHLHB2 protein.

As used herein, a "CAD susceptibility gene" refers to a gene that has a predisposing influence on the development of CAD in a subject.

As used herein, "coronary artery disease" (CAD) refers to disorders and conditions related to the deposition of atheroma in the large- and medium-sized arteries serving the heart.

Coronary artery disease means clinical syndromes (including, but not limited to, angina, myocardial infarction, unstable angina, and sudden ischemic death) which are based on the pathology of coronary artery atheroma.

As used herein "BHLHB2 protein" refers to the BHLHB2 protein, peptide fragments thereof, mutants, variants, truncated forms of BHLHB2, and fusion proteins of BHLHB2.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a line graph showing the KAC LOD-score of chromosome 3.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention describes a CAD susceptibility gene, BHLHB2. BHLHB2, also known as DEC1, is a basic helix-loop-helix transcription factor and has been implicated in control of chondrocyte (Shen-M et al. BBRC, 236:294-289, 1997), neuronal (Boudjelal, Genes and Dev 11:2052-2065, 1997) and preadipocyte differentiation (Inuzuka-H et al. BBRC 265:664-668, 1999).

The present finding shows that BHLHB2, which is mapped to chromosome region 3p, shows linkage with DNA markers in CAD affected individuals. The BHLHB2 gene and amino acid sequences are known for many different species, e.g., the human BHLHB2 nucleic and amino acid sequences are available on genbank (<http://www.ncbi.nlm.nih.gov/>), under accession number AB043885 (formerly XM 005086), and the mouse BHLHB2 is available on genbank under accession number NM 011498.

Knowledge of the BHLHB2 sequence enables the development of novel antigene methods to modulate the expression of BHLHB2 and also enables the development of novel gene therapy techniques to treat CAD.

The sequence of human BHLHB2 protein, as disclosed in NM003670 and AB043885, is depicted in SEQ ID NO: 18, the cDNA sequence in SEQ ID NO: 19 and the genomic sequence in SEQ ID NO:20.

**5 Functional Assay**

- To further evaluate the role of BHLHB2 in CAD, various functional assays can be performed. For example techniques such as Northern analysis, *in situ* hybridization or expression profiling on cDNA microarrays can be used to further verify the association of BHLHB2 with CAD. In one example, a reporter-based assay may be devised to detect whether the BHLHB2
- 10 gene has a different transcription level and/or message stability compared to the same gene in a person not susceptible to CAD. Individuals who carry the BHLHB2 gene may exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and may display altered physiological abilities.
- 15 In another example, the level of BHLHB2 gene expression can be assayed by detecting and measuring BHLHB2 transcription. For example, RNA from a cell type or tissue known, or suspected of having CAD, can be isolated and tested utilizing hybridization or PCR techniques such as those described above. The isolated cells can be obtained from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the
- 20 assessment of cells to be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of BHLHB2. Such analyses can reveal both quantitative and qualitative aspects of the expression pattern of the BHLHB2 gene, including activation or inactivation of BHLHB2 gene expression.
- 25 In one embodiment of such a detection scheme, cDNAs are synthesized from the RNAs of interest (e.g., by reverse transcription of the RNA molecule into cDNA). A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR amplification reaction, or the like. For detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides.
- 30 Alternatively, enough amplified product can be made such that the product can be visualized

-7-

by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method.

Additionally, it is possible to perform BHLHB2 gene expression assays *in situ*, i.e., directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary (See, e.g., Nuovo, G. J., PCR In Situ Hybridization: Protocols And Applications, Raven Press, NY, 1992).

Alternatively, if a sufficient quantity of the appropriate cells can be obtained, standard Northern analysis can be performed to determine the level of mRNA expression of the BHLHB2 gene.

Also within the invention is the determination of whether BHLHB2 gene has a gene mutation compared to the wild-type gene. Alternative methods for the detection of BHLHB2 gene mutations in patient samples or other appropriate cell sources, may involve their amplification, for example, by PCR (the experimental embodiment set forth in U.S. Pat. No. 4, 683, 202), followed by the detection of the amplified molecules using techniques well known to those of skill in the art. The resulting amplified sequences can be compared to those which would be expected if the nucleic acid being amplified contained only normal copies of the BHLHB2 gene in order to determine whether a BHLHB2 gene mutation exists.

Additionally, well-known genotyping techniques can be performed to identify individuals carrying BHLHB2 gene mutations. Such techniques include, for example, TaqMan 5' nuclease assay, allele specific PCR, primer extension, mass spectrometry and Pyrosequencing (reviewed in Kwok, Pharmacogenomics 1: 95-100, 2000)

#### *Pathway mapping*

Also within the invention is the identification and elucidation of the CAD biochemical/signal transduction pathway of which BHLHB2 is a component. In particular, the invention includes identifying the other components of the BHLHB2 CAD biochemical pathway. In this way it



is possible to identify the specific critical signaling pathway which links the disease stimulus to the cell's response and enables the identification of new potential targets for therapy intervention.

- 5 As used herein, a BHLHB2 "target molecule" is a molecule in the CAD biochemical pathway with which BHLHB2 binds or interacts, directly or indirectly, with, or is a molecule that regulates the expression of the CAD gene or translation of the protein. For example, the target molecule can be a protein which directly interacts with BHLHB2, or can be a protein which does not itself directly interact with the BHLHB2, but which is a component of the
- 10 BHLHB2 CAD biochemical pathway. In one example, the target molecule can be a cell membrane or a cytoplasmic molecule. In another example, the target molecule can be an intercellular protein or a protein which facilitates the association of downstream or upstream signaling molecules with the BHLHB2 protein.
- 15 According to a further aspect of the invention there is provided the use of the BHLHB2 protein in research to identify further gene targets implicated in CAD. Methods for identifying proteins which interact with BHLHB2 are known in the art, e.g., the two-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. Cell 72:223-232, 1993) or using cell culture techniques to identify binding partners.
- 20 The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a BHLHB2 protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g.,
- 25 GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a BHLHB2-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity
- 30 allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter

-9-

gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the "target" protein which interacts with the BHLHB2 protein.

- 5 Alternatively, binding partners for BHLHB2 can be identified using cell culture techniques or using cells obtained directly from a CAD patient. The method includes isolating the BHLHB2 protein from the cell and determining the identity of its target molecule. Initial screening can be accomplished by Western blot analysis to analyse immunochemically, e.g., using antibodies against the BHLHB2, the size of BHLHB2 -target molecule complex.
- 10 Further analysis of the complex will reveal the identity of the target molecule.

The gene and protein encoded by the target molecule is also a potential target for therapeutic intervention in CAD disease, for instance in the development of antisense nucleic acid targeted to the mRNA; or more widely in the identification or development of chemical or

15 hormonal therapeutic agents. The person skilled in the art is also capable of devising screening assays to identify compounds (chemical or biological) that modulate (activate or inhibit) the identified gene, which compounds may prove useful as therapeutic agents in treating or preventing CAD.

20 *BHLHB2 Proteins and Polypeptides*

BHLHB2 proteins, peptide fragments, mutated, and truncated forms of the BHLHB2, and/or BHLHB2 fusion proteins, can be prepared for a variety of uses, including but not limited to the generation of antibodies, as reagents in diagnostic assays, in the identification of other cellular gene products involved in the pathogenesis of CAD, as reagents in assays for

25 screening for compounds that can be used in the treatment of CAD, and as pharmaceutical reagents useful in the treatment of CAD.

A variety of host-expression vector systems may be utilized to express the BHLHB2 nucleotide sequences of the invention. The expression systems that may be used for purposes

30 of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli*,

*B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing BHLHB2 nucleotide sequences or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harbouring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or  
5 from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the BHLHB2 gene product being expressed. For  
10 example, when a large quantity of BHLHB2 is to be produced, for the generation of pharmaceutical compositions of BHLHB2 or for raising antibodies to the BHLHB2 protein, for example, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791, 1983), in which the BHLHB2  
15 coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109, 1985; Van Heeke & Schuster, J. Biol. Chem. 264:5503-5509, 1989); and the like. PGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be  
20 purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

25 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the BHLHB2 nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of  
30 the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and

-11-

capable of expressing the BHLHB2 in infected hosts. (E.g., See Logan & Shenk, , Proc. Natl. Acad. Sci. USA 81:3655-3659, 1984).

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the BHLHB2 sequence described above may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the BHLHB2. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the BHLHB2.

Alternatively, any fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al., Proc. Natl. Acad. Sci. USA 88:8972-8976, 1991). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni.2+. nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

The BHLHB2 protein can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, and non-human primates, for example, baboons, monkeys, and chimpanzees may be used to generate

-12-

**BHLHB2 transgenic animals.**

Any technique known in the art may be used to introduce the BHLHB2 transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci. USA 82:6148-6152, 1985); gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321, 1989); electroporation of embryos (Lo, Mol. Cell. Biol. 3:1803-1814, 1983); and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723, 1989); etc. For a review of such techniques, see Gordon, Transgenic Animals, Intl. Rev. Cytol. 115:171-229, 1989, which is incorporated by reference herein in its entirety.

The present invention provides for transgenic animals that carry the BHLHB2 transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals. The transgene may be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko, M. et al., Proc. Natl. Acad. Sci. USA 89:6232-6236, 1992). Once transgenic animals have been generated, the expression of the recombinant BHLHB2 gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include but are not limited to Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and RT-PCR. Samples of BHLHB2 gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the BHLHB2 transgene product.

***Antibodies to BHLHB2 Proteins***

Antibodies that specifically recognize one or more epitopes of BHLHB2 or peptide fragments

of the BHLHB2 are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of  
5 any of the above.

The antibodies of the invention may be used, for example, in the detection of the BHLHB2 in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of BHLHB2. Such  
10 antibodies may also be utilized in conjunction with, for example, compound screening schemes for the evaluation of the effect of test compounds on expression and/or activity of the BHLHB2 gene product. Additionally, such antibodies can be used in conjunction with the gene therapy techniques described, for example, evaluate the normal and/or engineered BHLHB2-expressing cells prior to their introduction into the patient. Such antibodies may  
15 additionally be used as a method for the inhibition of abnormal BHLHB2 activity. Thus, such antibodies may, therefore, be utilized as part of CAD treatment methods.

Methods of making and detecting labelled antibodies are well known (Campbell; Monoclonal Antibody Technology, in: Laboratory Techniques in Biochemistry and Molecular Biology,  
20 Volume 13. Eds: Burdon R et al. Elsevier, Amsterdam (1984)). The term antibody includes both monoclonal antibodies, which are a substantially homogeneous population, and polyclonal antibodies which are heterogeneous populations. The term also includes inter alia, humanised and chimeric antibodies. Monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art, such as from hybridoma cells, phage  
25 display libraries or other methods. Monoclonal antibodies may be inter alia, human, rat or mouse derived. For the production of human monoclonal antibodies, hybridoma cells may be prepared by fusing spleen cells from an immunised animal, e.g. a mouse, with a tumour cell. Appropriately secreting hybridoma cells may thereafter be selected (Koehler & Milstein, Nature 256:495-497 (1975); Cole et al., "Monoclonal antibodies and Cancer Therapy", Alan

R Liss Inc, New York N.Y. pp 77-96 (1985)). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.

Polyclonal antibodies can be generated by immunisation of an animal (such as a mouse, rat, goat, horse, sheep etc) with BHLHB2.

Rodent antibodies may be humanised using recombinant DNA technology according to techniques known in the art. Alternatively, chimeric antibodies, single chain antibodies, Fab fragments may also be developed against the polypeptides of the invention (Huse et al., Science 256:1275-1281 (1989)), using skills known in the art. Antibodies so produced have a number of uses which will be evident to the molecular biologist or immunologist skilled in the art. Such uses include, but are not limited to, monitoring enzyme expression, development of assays to measure enzyme activity and use as a therapeutic agent. Enzyme linked immunosorbant assays (ELISAs) are well known in the art and would be particularly suitable for detecting the BHLHB2 or polypeptide fragments thereof in a test sample.

#### *Screening Assay*

The invention also provides a method for identifying modulators, i.e., test compounds (e.g., peptides, peptidomimetics, small molecules or other drugs) which modulate the activity of the BHLHB2 gene or protein.

In one example, the invention provides methods for screening for test compounds for use in the treatment of CAD by screening for test compounds that modulate the activity of the BHLHB2 protein, or a portion thereof. The test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries. The method can be a cell-based method or a cell free method. The screening methods according to the invention may be operated using conventional procedures, for example by bringing the test compound or compounds to be screened and an appropriate substrate into contact with the BHLHB2 polypeptide, or a cell capable of producing it, or a cell membrane preparation thereof, and determining affinity for the BHLHB2 polypeptide in accordance with standard techniques.

Any compound identified in this way may prove useful in the treatment of CAD in humans and/or other animals. The invention thus extends to a compound selected through its ability to regulate the activity of the BHLHB2 protein *in vivo* as primarily determined in a screening assay utilising a BHLHB2 polypeptide or a homologue or fragment thereof, or a gene coding therefore for use in the treatment of a disease in which the over- or under-activity or unregulated activity of the protein is implicated.

According to a further aspect of the invention there is provided a screening assay or method for identifying potential CAD therapeutic compounds comprising contacting an assay system capable of detecting the effect of a test compound against expression level of BHLHB2, with a test compound and assessing the change in expression level of BHLHB2. Compounds that modulate the expression of DNA or RNA of the BHLHB2 polypeptide may be detected by a variety of assay systems. A suitable assay system may be a simple "yes/no" assay to determine whether there is a change in expression of a reporter gene, such as beta-galactosidase, luciferase, green fluorescent protein or others known to the person skilled in the art (reviewed by Naylor, Biochem. Pharmacol. 58:749-57, 1999). The assay system may be made quantitative by comparing the expression or function of a test sample with the levels of expression or function in a standard sample. Systems in which transcription factors are used to stimulate a positive output, such as transcription of a reporter gene, are generally referred to as "one-hybrid systems" (Wang, M.M. and Reed, R.R. Nature 364:121-126, 1993). Using a transcription factor to stimulate a negative output (growth inhibition) may thus be referred to as a "reverse one-hybrid system" (Vidal et al, 1996, *supra*). Therefore, in an embodiment of the present invention, a reporter gene is placed under the control of the BHLHB2 promoter.

In a further aspect of the invention a cell or cell line comprising a reporter gene under the control of the BHLHB2 promoter is provided.

According to another aspect of the present invention there is provided a method of screening for a compound potentially useful for treatment of CAD, which comprises assaying the compound for its ability to modulate the activity or amount of BHLHB2. Preferably the assay is selected from:



-16-

- i) measurement of BHLHB2 activity using a cell line which expresses the BHLHB2 polypeptide or using purified BHLHB2 polypeptide; and
- ii) measurement of BHLHB2 transcription or translation in a cell line expressing the BHLHB2 polypeptide.

5

Thus, in a further aspect of the invention, cell cultures expressing the BHLHB2 polypeptide can be used in a screen for therapeutic agents. Effects of test compounds may be assayed by changes in mRNA or protein of BHLHB2. As described above, cells (i.e. mammalian, bacterial, etc) can be engineered to express the BHLHB2 polypeptide.

10

Thus, according to a further aspect of the invention there is provided a method of testing potential therapeutic agents for the ability to suppress the CAD phenotype comprising contacting a test compound with a cell engineered to express the BHLHB2 polypeptide; and determining whether said test compound suppressed expression of the BHLHB2 polypeptide.

15

We also provide a method for identifying inhibitors of transcription of BHLHB2, which method comprises contacting a potential therapeutic agent with a cell or cell line as described above and determining inhibition of BHLHB2 transcription by the potential therapeutic agent by reference to a lack of or reduction in expression of the reporter gene.

20

Any convenient test compound or library of test compounds may be used in conjunction with the test assay. Particular test compounds include low molecular weight chemical compounds (preferably with a molecular weight less than 1500 daltons) suitable as pharmaceutical or veterinary agents for human or animal use, or compounds for non-administered use such as cleaning/sterilising agents or for agricultural use. Test compounds may also be biological in nature, such as antibodies.

25

According to a further aspect of the invention there is provided a compound identified by a screening method as defined herein.

30

According to another aspect of the present invention there is provided use of a compound able to modulate the activity or amount of BHLHB2 in the preparation of a medicament for the

treatment of CAD. Modulation of the amount of BHLHB2 by a compound may be brought about for example through altered gene expression level or message stability. Modulation of the activity of BHLHB2 by a compound may also be brought about for example through compound binding to the BHLHB2 protein. In one embodiment, modulation of BHLHB2 comprises use of a compound able to reduce the activity or amount of BHLHB2. In another embodiment, modulation of BHLHB2 comprises use of a compound able to increase the activity or amount of BHLHB2.

#### *Diagnostic test*

10 Methods for the diagnosis of CAD may, for example, utilize reagents such as the BHLHB2 nucleotide sequences and BHLHB2 antibodies. Specifically, such reagents may be used, for example, for: (1) the detection of the presence of BHLHB2 gene mutations, or the detection of either over- or under-expression of BHLHB2 mRNA relative to a control; (2) the detection of either an over- or an under-abundance of BHLHB2 gene product relative to a control; and (3)  
15 the detection of perturbations or abnormalities in the signal transduction pathway mediated by BHLHB2.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific BHLHB2 nucleotide sequence or BHLHB2  
20 antibody reagent described herein, which may be conveniently used, e.g., in clinical settings, to diagnose patients exhibiting body weight disorder abnormalities.

For the detection of BHLHB2 mutations, any nucleated cell can be used as a starting source for genomic nucleic acid. For the detection of BHLHB2 gene expression or BHLHB2 gene  
25 products, any cell type or tissue in which the BHLHB2 gene is expressed can be used.

#### *Detection of BHLHB2 polymorphisms*

Knowledge of polymorphisms can be of assistance in identifying patients susceptible to  
30 particular diseases and those most suited to therapy with particular pharmaceutical agents (the latter is often termed "pharmacogenetics"). Pharmacogenetics can also be used in

-18-

pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), *Clinical Chemistry*, 43, 254; Marshall (1997), *Nature Biotechnology*, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), *Nature Biotechnology*, 16, 33.

The present inventors have identified a number of polymorphisms within and around the BHLHB2 gene with demonstrable genetic association to coronary artery disease (CAD). The type and position of polymorphisms, which are identified in Table 3, are identified according to the position in Genbank ID:AB043885. Tables 4 and 5 provide sequence adjacent to the polymorphism site, which sequence can be used to unambiguously locate the position of the polymorphism in a nucleic acid sample, without reference to AB043885. SEQ ID Nos: 1 – 17 provide sequence of the polymorphism and sequence adjacent the polymorphism.

15

According to one aspect of the present invention there is provided a method for the diagnosis of a nucleotide polymorphism associated with CAD, which method comprises determining the sequence of the nucleotide at position 61 of any one of SEQ ID NOs: 1 to 5, 7, 8 and 10 to 17, or determining the number of CA repeats starting at position 61 of SEQ ID NO: 6, or the number of GT repeats starting at position 61 of SEQ ID NO: 9, and determining the status of the human by reference to polymorphism(s) detected.

The term human includes both a human having or suspected of having inflammatory bowel disease and an asymptomatic human who may be tested for predisposition or susceptibility to CAD. At each position the human may be homozygous for an allele or the human may be a heterozygote.

In one embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 1) is the presence of G and/or A.

30

-19-

In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 2) is the presence of A and/or C.

- 5 In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 3) is the presence of C and/or T.

- 10 In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 4) is the presence of C and/or T.

- 15 In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 5) is the presence of C and/or T.

- In another embodiment of the invention preferably the method of diagnosis described herein is one in which the number of CA repeats starting at position 61 (according to SEQ ID NO: 6) is determined.

20

- In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 7) is the presence of T and/or C.

- 25 In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 8) is the presence of A and/or G.

- 30 In another embodiment of the invention preferably the method of diagnosis described herein is one in which the number of GT repeats starting at position 61 (according to SEQ ID NO: 9) is determined.

-20-

In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 10) is the presence of G and/or C.

- 5 In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 11) is the presence of G and/or T.

- 10 In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 12) is the presence of G and/or A.

- In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 15 13) is the presence of A and/or G.

- In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 14) is the presence of A and/or T.

20

- In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 15) is the presence of A and/or C.

- 25 In another embodiment of the invention preferably the method of diagnosis described herein is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 16) is the presence of G and/or A.

- In another embodiment of the invention preferably the method of diagnosis described herein 30 is one in which the single nucleotide polymorphism at position 61 (according to SEQ ID NO: 17) is the presence of A and/or T.

The method for diagnosis is preferably one in which the sequence is determined by a method selected from amplification refractory mutation system and restriction fragment length polymorphism.

- 5 In another aspect of the invention we provide a method for the diagnosis or prognosis or inflammatory bowel disease, which method comprises:
- i) obtaining sample nucleic acid from an individual,
  - ii) detecting the presence or absence of a variant nucleotide at position 61 relative to one or more of the sequences disclosed in SEQ ID NO: 1 to 5, 7, 8 and 10 to 17, or detecting the  
10 number of CA repeats starting at position 61 of SEQ ID NO: 6, or the number of GT repeats starting at position 61 of SEQ ID NO: 9; and,
  - iii) determining the status of the individual by reference to the particular variant polymorphism.
- 15 The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before use in the analysis of  
20 BHLHB2 variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures, which may be used to detect the presence or absence of the various SNPs of the invention. In general, the detection of allelic variation requires a mutation discrimination  
25 technique, optionally an amplification reaction and a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a number of signal generation systems, a selection of which is listed in List 1. Further amplification techniques are listed in List 2. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997;  
30 and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2<sup>nd</sup> Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

**Abbreviations:**

<b>ALEX™</b>	<b>Amplification refractory mutation system linear extension</b>
<b>APEX</b>	<b>Arrayed primer extension</b>
<b>ARMST™</b>	<b>Amplification refractory mutation system</b>
<b>b-DNA</b>	<b>Branched DNA</b>
<b>CMC</b>	<b>Chemical mismatch cleavage</b>
<b>Bp</b>	<b>base pair</b>
<b>COPS</b>	<b>Competitive oligonucleotide priming system</b>
<b>DGGE</b>	<b>Denaturing gradient gel electrophoresis</b>
<b>FRET</b>	<b>Fluorescence resonance energy transfer</b>
<b>LCR</b>	<b>Ligase chain reaction</b>
<b>MASDA</b>	<b>Multiple allele specific diagnostic assay</b>
<b>NASBA</b>	<b>Nucleic acid sequence based amplification</b>
<b>OLA</b>	<b>Oligonucleotide ligation assay</b>
<b>PCR</b>	<b>Polymerase chain reaction</b>
<b>PTT</b>	<b>Protein truncation test</b>
<b>RFLP</b>	<b>Restriction fragment length polymorphism</b>
<b>SDA</b>	<b>Strand displacement amplification</b>
<b>SNP</b>	<b>Single nucleotide polymorphism</b>
<b>SSCP</b>	<b>Single-strand conformation polymorphism analysis</b>
<b>SSR</b>	<b>Self sustained replication</b>
<b>TGGE</b>	<b>Temperature gradient gel electrophoresis</b>

**Table 1 - Mutation Detection Techniques****General:** DNA sequencing, Sequencing by hybridisation

**Scanning:** PTT\*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

\* Note: not useful for detection of promoter polymorphisms.

-23-

**Hybridisation Based**

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La

- 5 Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)

Extension Based: ARMST™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

Incorporation Based: Mini-sequencing, APEX

- 10 Restriction Enzyme Based: RFLP, Restriction site generating PCR

Ligation Based: OLA

Other: Invader assay

List 1 - Signal Generation or Detection Systems

- 15 Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

- 20 List 2 - Further Amplification Methods

SSR, NASBA, LCR, SDA, b-DNA

Preferred mutation detection techniques include ARMST™, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, and restriction site based PCR and FRET techniques.

- 25 Particularly preferred methods include Taqman, ARMST™ and RFLP based methods. Taqman is an especially preferred method.

- 30 Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels.



In a further aspect, the diagnostic methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to CAD, and the present invention may be used to recognise individuals who are particularly at risk from developing CAD conditions.

- 5 In a further aspect, the diagnostic methods of the invention are used in the development of new drug therapies, which selectively target one or more allelic variants identified herein. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the  
10 disease process whilst minimising effects on other variants.

- In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes. The person of ordinary skill will be able to design and implement  
15 diagnostic procedures based on the detection of restriction fragment length polymorphism due to the loss or gain of one or more of the sites.

The invention further provides nucleotide primers which detect the polymorphisms of the invention.

20

The invention further provides nucleotide probes which can detect the polymorphisms of the invention.

- According to another aspect of the present invention a person of ordinary skill will be able to  
25 design allele specific primers or probes capable of detecting a polymorphism at position 61 at one or more of: SEQ ID NO: 1 to 17.

- An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between  
30 alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMS<sup>TM</sup> assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

-25-

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the  
5 properties of the primer.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20;  
10 Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1<sup>st</sup> Edition. If required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a polymorphism at position 61 of any one of SEQ  
15 ID NOs: 1 to 5, 7, 8 and 10 to 17, or a variant number of CA repeats starting at position 61 of SEQ ID NO: 6, or a variant number of GT repeats starting at position 61 of SEQ ID NO: 9.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides. Representative examples  
20 of oligonucleotide probes are those identified in SEQ ID NO: 1 to 17, but wherein the nucleotide at position 31 is one or other of the polymorphic alleles.

The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently  
25 up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.  
30 According to another aspect of the present invention there is provided a diagnostic kit comprising a diagnostic primer of the invention and/or an allele-specific oligonucleotide primer of the invention.

The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

- 5 In another aspect of the invention, the single nucleotide polymorphisms of this invention may be used as genetic markers for this region in linkage studies.

*Detection of the CAD Gene and Transcripts*

- BHLHB2 gene transcripts and mutations within the BHLHB2 gene can be detected by  
10 utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as the starting point for such assay techniques, and may be isolated according to standard nucleic acid preparation procedures which are well known to those of skill in the art.

- DNA may be used in hybridization or amplification assays of biological samples to detect  
15 abnormalities involving BHLHB2 gene structure or gene regulatory elements, including point mutations, insertions, deletions and chromosomal rearrangements. Such assays may include, but are not limited to, Southern analyses, single stranded conformational polymorphism analyses (SSCP), and PCR analyses.

- 20 Such diagnostic methods for the detection of BHLHB2 gene-specific mutations can involve for example, contacting and incubating nucleic acids including recombinant DNA molecules, cloned genes or degenerate variants thereof, obtained from a sample, for example, derived from a patient sample or other appropriate cellular source, with one or more labeled nucleic acid reagents including recombinant DNA molecules, under conditions favorable for the  
25 specific annealing of these reagents to their complementary sequences within the BHLHB2 gene. Preferably, the lengths of these nucleic acid reagents are at least 15 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid: BHLHB2 molecule hybrid. The presence of nucleic acids which have hybridized, if any such molecules exist, is then detected. Using such a detection scheme, the nucleic acid from the cell type or  
30 tissue of interest can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads. Detection of the remaining, annealed, labeled BHLHB2 nucleic acid reagents is accomplished using standard

-27-

techniques well-known to those in the art. The BHLHB2 gene sequences to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal BHLHB2 gene sequence in order to determine whether a BHLHB2 gene mutation is present.

5 *Detection of the BHLHB2 Gene Products*

Antibodies directed against wild type or mutant BHLHB2 gene products or conserved variants or peptide fragments thereof, can also be used as CAD diagnostics. Such diagnostic methods, can be used to detect abnormalities in the level of BHLHB2 gene expression, or abnormalities in the structure and/or temporal, tissue, cellular, or subcellular location of the  
10 BHLHB2, and may be performed in vivo or in vitro, such as, for example, on biopsy tissue.

For example, antibodies directed to epitopes of the BHLHB2 can be used in vivo to detect the pattern and level of expression of the BHLHB2 in the body. Such antibodies can be labeled, and injected into a subject in order to visualize binding to the BHLHB2 expressed in the body  
15 using methods such as X-rays, CAT-scans, or MRI.

Additionally, any BHLHB2 fusion protein or BHLHB2 conjugated protein whose presence can be detected, can be administered. For example, BHLHB2 fusion or conjugated proteins labeled with a radio-opaque or other appropriate compound can be administered and  
20 visualized in vivo, as discussed, above for labeled antibodies.

Alternatively, immunoassays or fusion protein detection assays, as described above, can be utilized on biopsy and autopsy samples in vitro to permit assessment of the expression pattern of the BHLHB2.

25

The tissue or cell type to be analyzed will generally include those which are known, or suspected, to express the BHLHB2 gene. The protein isolation methods employed herein can, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring  
30 Harbor, N.Y., 1989), which is incorporated herein by reference in its entirety. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from

-28-

culture may be a necessary step in the assessment of cells that could be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the BHLHB2 gene.

3 *Gene therapy*

The invention encompasses gene therapy methods and compositions for treating and preventing CAD.

In one example, the loss of normal BHLHB2 gene product function can result in the  
10 development of CAD. Increasing BHLHB2 gene product activity, or activation of the BHLHB2 pathway (e.g., downstream activation) would therefore facilitate progress in individuals exhibiting a deficient level of BHLHB2 gene expression and/or BHLHB2 activity.

Alternatively, CAD may be ameliorated by decreasing the level of BHLHB2 gene expression,  
15 and/or BHLHB2 gene activity, and/or downregulating activity of the BHLHB2 pathway (e.g., by targeting downstream signaling events). Different approaches are discussed below.

*Inhibition of BHLHB2 Expression or BHLHB2 Activity*

Any method that neutralizes or inhibits expression of the BHLHB2 gene (either transcription  
20 or translation) can be used to prevent or treat CAD.

For example, the administration of soluble peptides, proteins, fusion proteins, or antibodies  
(including anti-idiotypic antibodies) that bind to and "neutralize" circulating BHLHB2 can be  
used. Such BHLHB2 neutralizing peptides, proteins, fusion proteins, anti-idiotypic antibodies  
25 or Fabs are administered to a subject in amounts sufficient to treat or prevent CAD.

In an alternate embodiment, therapy can be designed to reduce the level of endogenous  
BHLHB2 gene expression, for example, using antisense or ribozyme approaches to inhibit or  
prevent translation of BHLHB2 mRNA-transcripts; triple helix approaches to inhibit  
30 transcription of the BHLHB2 gene; or targeted homologous recombination to inactivate or

"knock out" the BHLHB2 gene or its endogenous promoter. Antisense, ribozyme or DNA constructs can be administered directly to the site containing the target cells; or can be directed to the target cells.

5 Antisense approaches involve the design of oligonucleotides (either DNA or RNA) that are complementary to BHLHB2 mRNA. The antisense oligonucleotides will bind to the complementary BHLHB2 mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity  
10 to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still  
15 form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, for example, the 5'  
20 untranslated sequence up to and including the AUG initiation codon, should work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. Thus, oligonucleotides complementary to either the 5'- or 3'-non-translated, non-coding regions of the BHLHB2 can be used in an antisense approach to inhibit translation of  
25 endogenous BHLHB2 mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of BHLHB2 mRNA, antisense nucleic acids should be at least  
30 six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50

-30-

nucleotides in length. In specific aspects, the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides, or at least 50 nucleotides in length.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

While antisense nucleotides complementary to the BHLHB2 coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred. The antisense molecules should be delivered to cells which express the BHLHB2 *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells; for example, antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically.

Ribozyme molecules designed to catalytically cleave BHLHB2 mRNA transcripts can also be used to prevent translation of BHLHB2 mRNA and expression of BHLHB2. (See, e.g., WO90/11364; Sarver et al., Science 247:1222-1225, 1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy BHLHB2 mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two

-31-

bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature 334:585-591, 1988. There are hundreds of potential hammerhead ribozyme cleavage sites within the nucleotide sequence of human BHLHB2 cDNA. Preferably the ribozyme is engineered so that the cleavage  
5 recognition site is located near the 5' end of the BHLHB2 mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one which occurs naturally in Tetrahymena Thermophila  
10 (known as the IVS, or L-19 IVS RNA) and which has been extensively described by Thomas Cech and collaborators (Zaug, et al., Science 224:574-578, 1984; Zaug and Cech, Science 231:470-475, 1986; Zaug, et al., Nature 324:429-433, 1986; patent application No. WO 88/04300; Been and Cech, Cell 47:207-216, 1986). The Cech-type ribozymes have an eight  
15 basepair active site that hybridizes to a target RNA sequence, whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes that target eight basepair active site sequences that are present in BHLHB2.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the  
20 BHLHB2 in vivo. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous BHLHB2 messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

25 In an alternative embodiment for neutralizing circulating BHLHB2, cells that are genetically engineered to express such soluble or secreted forms of BHLHB2 can be administered to a patient, whereupon they will serve as "bioreactors" in vivo to provide a continuous supply of the neutralizing protein.  
30



-32-

Endogenous BHLHB2 gene expression can also be reduced by inactivating or "knocking out" the BHLHB2 gene or its promoter using targeted homologous recombination. (E.g., see Smithies et al., Nature 317:230-234, 1985; Thomas & Capecchi, Cell 51:503-512, 1987; Thompson et al., Cell 5:313-321, 1989; each of which is incorporated by reference herein in its entirety).

In yet another embodiment of the invention, the activity of BHLHB2 can be reduced using a "dominant negative" approach to effectuate BHLHB2. To this end, constructs that encode defective BHLHB2s can be used in gene therapy approaches to diminish the activity of the BHLHB2 in appropriate target cells.

*Restoration or Increase in BHLHB2 Expression or Activity*

With respect to an increase in the level of BHLHB2 gene expression and/or BHLHB2 gene product activity, BHLHB2 nucleic acid sequences can be utilized for the treatment of CAD. Where the cause of CAD is a defective BHLHB2 gene, treatment can be administered, for example, in the form of gene replacement therapy. Specifically, one or more copies of a normal BHLHB2 gene or a portion of the BHLHB2 gene that directs the production of a BHLHB2 gene product exhibiting normal function, can be inserted into the appropriate cells within a patient or animal subject, using vectors which include, but are not limited to, adenovirus, adeno-associated virus, retrovirus, and herpes virus vectors, in addition to other particles that introduce DNA into cells, such as liposomes.

Additional methods that can be utilized to increase the overall level of BHLHB2 gene expression and/or BHLHB2 activity include the introduction of appropriate BHLHB2-expressing cells, preferably autologous cells, into a patient at positions and in numbers which are sufficient to ameliorate the symptoms of CAD. Such cells can be either recombinant or non-recombinant. Among the cells that can be administered to increase the overall level of BHLHB2 gene expression in a patient are normal cells which express the BHLHB2 gene. The cells can be administered to the site of interest. Such cell-based gene therapy techniques are well known to those skilled in the art, see, for example, Anderson, et al., U.S. Pat. No. 5,399,349; Mulligan & Wilson, U.S. Pat. No. 5,460,959.

Finally, compounds, identified in the assays described above, that stimulate or enhance the signal transduced by activated BHLHB2, for example, by activating downstream signalling proteins in the BHLHB2 cascade, and thereby by-passing the defective BHLHB2. The formulation and mode of administration will depend upon the physico-chemical properties of the compound.

*Pharmaceutical composition containing the Identified Candidate Compound*

The compounds having the desired activity may be administered in a physiologically acceptable carrier to a CAD patient. Such compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular or intramuscular dosing or as a suppository for rectal dosing).

The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.

Suitable pharmaceutically acceptable excipients for a tablet formulation include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate, granulating and disintegrating agents such as corn starch or algenic acid; binding agents such as starch; lubricating agents such as magnesium stearate, stearic acid or talc; preservative agents such as ethyl or propyl p-hydroxybenzoate, and anti-oxidants, such as ascorbic acid. Tablet formulations may be uncoated or coated either to modify their disintegration and the subsequent absorption of the active ingredient within the gastrointestinal track, or to improve their stability and/or appearance, in either case, using conventional coating agents and procedures well known in the art.

Compositions for oral use may be in the form of hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin, or olive oil.

5 Aqueous suspensions generally contain the active ingredient in finely powdered form together with one or more suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as lecithin or condensation  
10 products of an alkylene oxide with fatty acids (for example polyoxyethylene stearate), or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example  
15 heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives (such as ethyl or propyl p-hydroxybenzoate, anti-  
20 oxidants (such as ascorbic acid), colouring agents, flavouring agents, and/or sweetening agents (such as sucrose, saccharine or aspartame).

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil (such as arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil (such as liquid  
25 paraffin). The oily suspensions may also contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set out above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

30 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water generally contain the active ingredient together with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents

-35-

and suspending agents are exemplified by those already mentioned above. Additional excipients such as sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of

5 oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, or a mineral oil, such as for example liquid paraffin or a mixture of any of these. Suitable emulsifying agents may be, for example, naturally-occurring gums such as gum acacia or gum tragacanth, naturally-occurring phosphatides such as soya bean, lecithin, an esters or partial esters derived from fatty acids and hexitol anhydrides (for example sorbitan monooleate) and

10 condensation products of the said partial esters with ethylene oxide such as polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening, flavouring and preservative agents.

Syrups and elixirs may be formulated with sweetening agents such as glycerol, propylene

15 glycol, sorbitol, aspartame or sucrose, and may also contain a demulcent, preservative, flavouring and/or colouring agent.

The pharmaceutical compositions may also be in the form of a sterile injectable aqueous or oily suspension, which may be formulated according to known procedures using one or more

20 of the appropriate dispersing or wetting agents and suspending agents, which have been mentioned above. A sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example a solution in 1,3-butanediol.

25 Suppository formulations may be prepared by mixing the active ingredient with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

30 Topical formulations, such as creams, ointments, gels and aqueous or oily solutions or suspensions, may generally be obtained by formulating an active ingredient with a

conventional, topically acceptable, vehicle or diluent using conventional procedure well known in the art.

Compositions for administration by insufflation may be in the form of a finely divided powder containing particles of average diameter of, for example,  $30\mu$  or much less, the powder itself comprising either active ingredient alone or diluted with one or more physiologically acceptable carriers such as lactose. The powder for insufflation is then conveniently retained in a capsule containing, for example, 1 to 50mg of active ingredient for use with a turbo-inhaler device, such as is used for insufflation of the known agent sodium cromoglycate.

Compositions for administration by inhalation may be in the form of a conventional pressurised aerosol arranged to dispense the active ingredient either as an aerosol containing finely divided solid or liquid droplets. Conventional aerosol propellants such as volatile fluorinated hydrocarbons or hydrocarbons may be used and the aerosol device is conveniently arranged to dispense a metered quantity of active ingredient.

For further information on Formulation the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition. Dosage unit forms will generally contain about 1 mg to about 500 mg of an active ingredient. For further information on Routes of Administration and Dosage Regimes the reader is referred to Chapter 25.3 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.

-37-

The size of the dose for therapeutic or prophylactic purposes of a compound will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well known principles of medicine.

- 5 In using a compound for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.5 mg to 75 mg per kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous administration, a dose in the range, for example, 0.5 mg to 30 mg per kg body weight will
- 10 generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.5 mg to 25 mg per kg body weight will be used. Oral administration is however preferred.

- It will be obvious to those skilled in the art to which the invention pertains, that various
- 15 changes and modifications may be made without departing from the scope of the invention defined by the claims.

P4V 03-07-22

**Example 1**

530 affected sib-pairs (ASPs) from 407 families with both sibs having CAD before 65 years were collected from hospitals in Sweden, Italy and Germany. All ASPs were recruited either from hospital discharge databases, existing research-based patient databases or from coronary  
5 care units.

Probands were individuals with documented myocardial infarction (MI) or other symptomatic acute coronary syndrome (ACS; defined as hospitalisation for one of the following indications: a) unstable angina; b) thrombolysis for suspected MI (localised ST-elevation in 2 or more ECG leads); c) emergency revascularisation for control of typical ischaemic chest  
10 pain at rest) first diagnosed before 65 years and confirmed by the physician. Affected sibs were individuals with confirmed MI, other symptomatic ACS as for the proband but in addition, chronic stable angina first diagnosed before 65 years and confirmed by physician, was included.

**Preparation of genomic DNA from blood cells**

15 Blood samples were stored at -80°C. Before extraction the samples were thawed at 37°C in a water bath. To extract the genomic DNA, using the PUREGENE DNA Isolation kit from Gentra Systems, the blood cells were added to 30ml of RBC lysis solution in a 50ml centrifuge tube. The mixture was inverted twice while incubating for 10minutes (min) at room temperature (RT). To separate the white cells from other lysed material, the mixture  
20 was centrifuged in a RT-7™ from Sorvall Ltd. at 2,000X g for 10min. Most of the supernatant was removed leaving approximately 100ml of residual solution to resuspend the cells in by vigorously vortexing. Following resuspension 10ml of cell lysis solution were added and mixed by pipetting. To digest any RNA, 50ml of RNase A solution were added to the lysate, which was then incubated at 37°C for 15min. After RNA digestion, 3.3ml of protein  
25 precipitation solution was added and the mixture was vortexed for 20seconds (s). To separate the proteins from the DNA, the mixture was again centrifuged at 2,000X g for 10min. The supernatant retaining the DNA was then poured off into another 50ml centrifuge tube containing 10ml of 100% isopropanol and mixed by inverting 50X. To separate the DNA from the aqueous solution, it was removed with an inoculating loop and washed in 10ml 70%

-39-

ethanol in a 50ml centrifuge tube. to remove any residual salt. The DNA was removed from the 70% ethanol using an inoculating loop and air dried briefly. To hydrate, the DNA was added to 1ml of DNA hydration solution in a 14ml centrifuge tube and this was rocked at RT overnight allowing the DNA to equilibrate. The resulting DNA samples were transferred to 1.5ml tubes and stored at -80°C. The concentration of extracted genomic DNA was quantified using the Fluorocount™ from Packard Instruments Co. The DNA was diluted to 4 ng/ml into a working plate.

Dispensing DNA from a working plate into several 96-well plates for subsequent polymerase chain reaction (PCR) amplification reactions was performed using the Hydra™ 96 from Robbins Scientific, Inc. The Hydra™ was programmed to dispense 5µl of DNA from each well of a 'working plate' into the corresponding wells of the required number of PCR plates. Before dispensing, the Hydra™ was washed with water. Following dispensing the Hydra™ was sterilised by washing with water, with 2% chlorox industrial, and again with water. The resulting PCR plates, containing 20ng of DNA in each well, were dried at 80°C for 1hr. The plates were stored at -20°C.

#### *Microsatellite genotyping for genome scan*

A total of 384 microsatellite markers were genotyped across the CAD ASP families. The majority of these were from the linkage mapping set 2.0 (Applied Biosystems). Additional markers were included to replace those excluded by error checking procedures. The amplification of microsatellite markers by PCR and subsequent pooling of the amplified products into panels were carried out using a RapidGene™ automated system from Oxagen Ltd. The PCR plates contained 20ng of dried genomic DNA in each well. The 1.5ml tubes contained 5mM of appropriate 'forward' oligonucleotide, 5mM of the corresponding 'reverse' oligonucleotide, 1X PCR buffer II, 2.5mM MgCl<sub>2</sub>, 1mM dNTP, and 0.06u/ml AmpliTaq Gold™ DNA polymerase in final volume of 1.2ml. During the run, 10µl of the appropriate PCR reaction mixture were dispensed into the wells of the plates. Following amplification the reactions were pooled into panels and the pool plates were sealed and stored at 4°C. Pooled DNA fragments generated from the amplification of microsatellite markers were separated by capillary electrophoresis using an ABI 3700 automated sequencer (PE Applied Biosystems,



Inc.). Products were sized using the programme ABI GENESCAN (version 3.0) (PE Biosystems) and genotypes assigned semi-automatically using the GENOTYPER software (version 2.0).

### 5 *Linkage Analysis Chromosome 3*

In a genome wide screen with 384 markers (average marker distance 9.2 cm) 530 affected sib-pairs were analysed from 407 families. In addition marker genotypes for at least one parent or unaffected sibs were available in 110 families.

- 10 The genotype data for chromosome 3 include 23 markers (see Fig 1) with an average distance of 9.8 cM. Linkage analysis was performed in Genehunter-Plus version 1.3 (Kruglyak et al, Am. J. Hum. Genet. 58, 1347-1363 (1996) and Kruglyak and Lander. Journal of Computational Biology 5:1-7 (1998)) using the 'all' scoring function, followed by calculation of LOD-scores in KAC as described by Kong and Cox Am. J. Hum. Genet. 61, 1179-1188
- 15 (1997). A maximum LOD-score of 3.45 was obtained at 9 cM, with the position given as the distance from the most telomeric marker D3S1297 (Fig 1). In table 2, LOD-scores for the three markers overlapping the peak are displayed.

Position	LOD	Marker
0.0	2.51	D3S1297
9.0	3.45	-
14.1	3.21	D3S1304
27.8	0.45	D3S1263

- 20 To assess the statistical significance of the obtained LOD-score we simulated marker genotype data under a model with no genetic effect, preserving the family structures and missing data patterns of the families in the study, using the observed marker allele frequencies. In 3600 replicates no LOD-scores as large as the one observed for the real data was observed for chromosome 3, indicating a p-value less than 0.001. Consideration of the
- 25 LOD-scores obtained on all autosomal chromosomes in each replicate resulted in an empirical genome-wide p-value of 0.01.

Genetic marker distances were obtained from the Marshfield map and translated to recombination fractions using the Kosambi mapping function. The marker allele frequencies were estimated from all genotyped individuals in the study.

- 5 Prior to the linkage analysis the genotype data went through quality control. This includes identification of half-sibs or unrelated individuals among the putative sib pairs using RELPAIR (Boehnke *et al.*, Am. J. Hum. Genet. 61:423-429. 1997), detection of Mendelian inconsistencies with PEDCHECK (O'Connell *et al.*, Am. J. Hum. Genet. 63:259-266 1998) and retyping of inconsistent marker-family combinations. Detected half-sib pairs were  
10 excluded from the linkage analysis described here.

#### *Associated gene identification*

- The highest linkage was found between makers D3S1297 and D3S1304, within this region lies the BHLHB2 gene. Further SNP mapping identified this gene as being associated with the  
15 CAD.

#### **Example 2**

##### *Identification of polymorphisms in BHLHB2, a coronary artery disease (CAD) susceptibility gene on chromosome 3p*

20

- According to the Ensembl genome assembly (build 31), the BHLHB2 gene consists of 5 exons covering a genomic distance of 5.7 kb. BLAST analysis using BHLHB2 cDNA suggests that there might be one or two additional 5' untranslated exons. The gene was screened for polymorphisms, and a selection of the identified polymorphisms were  
25 subsequently tested for association to CAD in a TDT material.

#### 1. DNA sequencing of BHLHB2 exons 1-5

Individual BHLHB2 exons were PCR amplified from genomic DNA of 24 unrelated individuals, using oligonucleotide primers designed in flanking intronic sequences.

The SNPs (or other polymorphisms) and their frequencies are shown in Table 3. Sequence flanking the polymorphisms is shown in Table 4, Table 5 shows sequence adjacent the polymorphisms.

<sup>10</sup> Additional public domain SNPs in the BHLHB2 gene were identified (dbSNP; <http://www.ncbi.nlm.nih.gov/SNP/>).

**Five SNPs discovered in Step 1 (rs1110261, rs2271566, rs2671757, rs908078, and DEC1az1494), were genotyped in at least 92 UK blood donor control DNAs obtained for validation of SNPs in the TDT collection. The results are shown in Table 3.**

One marker discovered in Step 1, DEC1azGTrep, was genotyped in a number of individuals from the TDT collection. The results are shown in Table 3.

Table 3

Internal identifier	Identifier	Position in gene (Genbank ID: AB043885)	*Allele change	Allele frequency (# of individuals)	"Single" p- value in fist TDT analysis
1	rs1110281	2176bp	G/A	no info	0.7382
2	rs1104976	2388bp	A/C	unconfirmed	
3	rs2271566	3643bp	C/T	C=84% / T=16% (3300)	0.9943
4	az0001116	3944bp	C/T/-	not polymorphic	
5	rs2671757	5112bp	C/T	C=81% / T=19% (3304)	0.0087
6	DEC1azCArep	5112-5133bp	(CA)n	no info	
7	rs908078	7002bp	T/C	T=84% / C=16% (3268)	0.7346
8	rs3205438	7082bp	A/G	not polymorphic	
9	DEC1azGTrep	7746-7775bp	(GT)n	no info	0.3538
10	DEC1az1131	7880bp	G/C	C=83% / T=17% (48)	
11	DEC1az1138	7885bp	G/T	G=67% / T=32% (48)	
12	DEC1az1140	7889bp	G/A	G=83% / A=17% (48)	
13	DEC1az1494	8243bp	A/G	A=81% / G=19% (48)	0.0660
14	rs1801739	8677bp	A/T	not polymorphic	
15	rs1058377	8905bp	A/C	not polymorphic	
16	rs1058380	8943bp	G/A	not polymorphic	
17	rs1058395	9065bp	A/T	not polymorphic	

TDTLIKE Terwilliger, (Am J Hum Genet 56:777-787, 1995).

Table 4

Internal identifier	5'flanking sequence
1	CCGCGAACAGCGCCGCCGAAGTTCCCAACAGGCAGGGAGAGGGCCGATCCGGGCTGGCAC
2	GGAGGCGACCGGGGCGCCTCTGCTCCGGAGGGGGCAGAGGAGGGAGGGAGCGCCGGGCAC
3	CCTCATCCAGACGCTCCGCTAGTGACAGACAGGAGCGCGCAGTGGCCCCGGCTCGCCGCGC
4	CAGGATGTACCCTGCCACATGTACCAAGTGTACAAGTCAAGACGGGGAATAAAGCGGAG
5	AGACAGGTGGCACCCGTTTTTTAAATTATTTAATTATATATATATATTATATATATATA
6	AGACAGGTGGCACCCGTTTTTTAAATTATTTAATTATATATATATATTATATATATATA
7	ATCAGACCCAGCTCCCAAAGTGATGGACTTCAAGGAAAAACCCAGCTCTCCGGCCAAAGG
8	ACTGCGTGCCAGTCATCCAGCGGACTTTCGCTCACTCGAGTGGGGAGCAGAGCGGCAGCG
9	CTGCAAGATTGTTGCATTGTGTATACTGAGATAATCTGAGGCATGGAGAGCAGATTCAGG
10	CTTTAAAGTCCTTTTGGCATAGGGAAGTCACGAAGGATTGCTTGACATCAGGAGACTTG
11	AAGCTCCTTTTGGCATAGGGAAGTCACGAAGGATTGCTTGACATCAGGAGACTTGGGGGG
12	TCCTTTTGGCATAGGGAAGTCACGAAGGATTGCTTGACATCAGGAGACTTGGGGGGGATT
13	CATAGCACGGTAGTGGTTTGGGGAGGTTTCCGCAGGTCTGCTCCCCACCCCTGCCTCGGA
14	CAACGGCATATGGAGTGTCTTATTGCTAAAAAGGATTCCGTCTCCTTCAAAGAAGTTTT
15	TATATAAATATATTAAGGAAAAATGTTTCAGATGTTTATTTGTATAATTACTTGATTG
16	TATTTGTATAATTACTTGATTCACACAGTGAGAAAAAATGAATGTATTCCTGTTTTTGAA
17	GAAGGTGTAAATGTAAATATTTTTATCTATGAGTAAATGTTAAGTAGTTGTTTTAAAA

Table 5

Internal identifier	3'flanking sequence
1	CCACGTCCCCGGGGTCTCAGTCCCTGGGTCAACGCAGAGAGGCTCGCGGTCCGCGGTGCT
2	GCGCCCGGTATCTTTCTGCGCTTGACTGGCCGGGAGGAAGGGGGTGACACTGGGGCACCC
3	ATGGAGCGGATCCCCAGCGCGCAACCACCCCCCGCCTGCCTGCCCAAAGCACCGGGACTG
4	GAGGACAGCAAGGTAAGCAAGTGCACCCCTAGGGACCCTGCGCTCAGCCCCTCGCGCGCG
5	ACACACACACACACACACATATATGAGTGTATCTGTCTATCTTTTAAAAGCATGACC
6	TATATGAGTGTATCTGTCTATCTTTTAAAAGCATGACCTACAGACTTAAACAGCCAAC
7	TGGGAAGTCTCTGGGAAAACTGCGTGCCAGTCATCCAGCGGACTTTCGCTCACTCGAGT
8	CACGGACACAGACAGTGGCTATGGAGGAGAATCGGAGAAGGGCGACTTGCGCAGTGAGCA
9	ATGTGCGTGTGCGTGCACATGTGTGCCTGCGTGTTGGTATAGGACTTTAAAGCTCCTTTT
10	GGGGGATTGTAGCAGACGTCTGGGCTTTTCCCCACCCAGAGAATAGCCCCCTTCGATACA
11	ATTGTAGCAGACGTCTGGGCTTTTCCCCACCCAGAGAATAGCCCCCTTCGATACACATCA
12	TAGCAGACGTCTGGGCTTTTCCCCACCCAGAGAATAGCCCCCTTCGATACACATCAGCTG
13	GAATAAAGAGAATGTAGTTCCTACTCAGGCTTTCGTAGTGATTAGCTTACTAAGGAACT
14	TTTTTGGTCCAGAGTACTTGTTCCTCCGATGTGTCCAGCCAGCTCCGCAGCAGCTTTTCA
15	CACAGTGAGAAAAAATGAATGTATTCCTGTTTTTGAAGAGAAGAATAATTTTTTTTCT
16	AGAAGAATAATTTTTTTTCTCTAGGGAGAGGTACAGTGTTTATATTTTGGAGCCTTCC
17	ACTTAATAAAATAATTCTTTTCTGTGGAAGAGAAAGATGGTCTCCTGAGTTTTTAAAA

1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17

**CLAIMS:**

1. A method of identifying a test compound that modulates the expression of BHLHB2 gene comprising:

contacting a cell capable of expressing BHLHB2 gene with a test compound; and  
5 determining the level of expression of the BHLHB2 gene in the presence of the test compound, wherein a decrease or an increase in expression of the BHLHB2 gene, as compared to the level of expression of a BHLHB2 gene in the absence of the compound, is indicative that the test compound modulates BHLHB2 gene expression.

10 2. A method of identifying a test compound that modulates the activity of a BHLHB2 protein comprising:

contacting the BHLHB2 protein with a test compound; and  
determining the level of activity of the BHLHB2 protein in the presence of the  
compound, wherein a decrease or an increase in BHLHB2 protein activity, as compared to the  
15 level of activity of the BHLHB2 protein in the absence of the compound, is indicative that the test compound modulates BHLHB2 protein activity.

3. A method of treating a subject having CAD comprising administering an effective amount of the compound identified in claims 1 or 2.

20

4. Use of a compound identified in claims 1 or 2 in the preparation of a medicament for the treatment of CAD.

5. A method of treating a patient suffering from CAD comprising administering to said  
25 patient an effective amount of an antibody specific for protein BHLBH2.

6. A method of treating a patient suffering from CAD comprising administering to the patient an effective amount of an antisense molecule capable of binding to the mRNA of gene BHLBH2, wherein binding of the antisense molecule to the mRNA causes a decrease in  
30 expression of the protein product of gene BHLBH2.

-47-

7. A pharmaceutical composition comprising the compounds identified in claims 1 or 2, and a pharmaceutically acceptable adjuvant, diluent or carrier.

8. A method of making a pharmaceutical composition comprising:

- 5       contacting a cell capable of expressing BHLBH2 with a test compound;  
          determining the level of expression of BHLBH2 in the presence of the test  
compound; wherein a decrease or an increase in expression of BHLBH2, as compared to the  
level of expression of BHLBH2 in the absence of the compound, is indicative that the test  
compound modulates BHLBH2 gene expression; and  
10       formulating the test compound that modulates BHLBH2 into a pharmaceutical  
composition.

9. A method of making a pharmaceutical composition comprising:

- contacting a BHLBH2 protein with a test compound;  
15       determining the level of activity of the BHLBH2 protein in the presence of the  
compound, wherein a decrease or an increase in BHLBH2 protein activity, as compared to the  
level of activity of the BHLBH2 protein in the absence of the compound, is indicative that the  
test compound modulates BHLBH2 protein activity; and  
          formulating the test compound that modulates BHLBH2 protein activity into a  
20       pharmaceutical composition.

10. A method for determining if a BHLBH2 gene has an altered level of gene expression comprising:

- comparing the level of BHLBH2 gene expression in a cell from a patient having CAD  
25       with a control cell; and  
          determining the level of expression of the BHLBH2 gene in both cells, wherein a  
decrease or an increase in expression of the BHLBH2 gene, as compared to the level of  
expression of the BHLBH2 gene in the control cell, indicates that the BHLBH2 has altered  
gene expression.

30

11. A method for determining the level of a BHLBH2 protein in a CAD patient compared to a control comprising:



-48-

comparing the protein level of BHLBH2 in a cell from a patient having CAD with a control cell; and

determining the level of the BHLBH2 protein in both cells.

- 5 12. A method of identifying a binding partner of the BHLHB2 protein comprising:  
contacting a BHLHB2 protein with a test target protein; and  
determining if the test target protein can interact with the BHLHB2 protein, wherein  
interaction of the test target protein with BHLBH2 indicates that the test target protein is a  
BHLBH2 binding partner.

10

13. The method of claim 12, wherein the method further comprises:  
contacting a gene encoding the test target protein with a test compound; and  
determining the level of expression of the test target gene in the presence of the test  
compound, wherein a decrease or an increase in test target gene expression, as compared to  
15 the level of expression of the test target gene in the absence of the compound, is indicative  
that the test compound modulates expression of the test target gene and is useful in the  
treatment of CAD.

14. The method of claim 12, wherein the method further comprises:  
20 contacting the test target protein with a test compound; and  
determining the level of activity of the test target protein in the presence of the test  
compound, wherein a decrease or an increase in test target protein activity, as compared to the  
level of activity of the test target protein in the absence of the compound, is indicative that the  
test compound modulates test target protein activity and is useful in the treatment of CAD.

25

15. The method of any of claims 13 or 14, wherein the test compound is formulated into a  
pharmaceutical composition.

16. A method of treating a subject having CAD comprising administering an effective  
30 amount of the compound identified in claims 13 or 14.

-49-

17. Use of a compound identified in of any of claims 13 or 14 in the preparation of a medicament for the treatment of CAD.

18. A method of identifying other components of the CAD biochemical pathway of which  
5 BHLHB2 is a component.

19. A method of diagnosing CAD, or a susceptibility thereto in a subject, the method comprising:

determining the level of mRNA of BHLHB2 in a sample from a subject; and  
10 comparing the level of mRNA of BHLHB2 in the sample with a control, wherein a decrease or an increase in the level of mRNA of BHLHB2 in the sample compared to the control indicates that the subject has CAD , or a susceptibility thereto.

20. A method of diagnosing CAD or a susceptibility thereto in a subject, the method  
15 comprising:

determining the level of a BHLHB2 protein in a sample from a subject; and  
comparing the level of BHLHB2 protein in the sample with a control, wherein a decrease  
or an increase in the level of the protein in the sample compared to the control indicates that  
the subject has CAD , or a susceptibility thereto.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
21

-50-

**Abstract**

The present invention describes a Coronary artery disease (CAD) susceptibility gene and the use of this gene in the development of novel therapies to treat CAD.

5  
4  
3  
2  
1

## Sequence listing:

## SEQ ID No:1

CCGCGAACAGCGCCGCCGAAC TTCCCAACAGGCAGGGAGAGGGCCGATCCGGGCTGGCACR  
5 CCACGTCCCCGGGGTCTCAGTCCCTGGGTCAACGCAGAGAGGCTCGCGGTCCGCGGTGCT

## SEQ ID No:2

GGAGGCGACCGGGGCGCCTCTGCTCCGGAGGGGGCAGAGGAGGGAGGGAGCGCCGGGCACM  
GCGCCCGGTATCTTTCTGCGCTTGACTGGCCGGGAGGAAGGGGGTGACACTGGGGCACCC  
10

## SEQ ID No:3

CCTCATCCAGACGCTCCGCTAGTGCAGACAGGAGCGCGCAGTGGCCCCGGCTCGCCGCGCYATGGAGCGG  
ATCCCCAGCGCGCAACCACCCCCCGCCTGCCTGCCCAAAGCACCGGGACTG

## 15 SEQ ID No:4

CAGGATGTACCCTGCCCACATGTACCAAGTGTACAAGTCAAGACGGGGAATAAAGCGGAGN  
GAGGACAGCAAGGTAAGCAAGTGACCCCCTAGGGACCCTGCGCTCAGCCCCTCGCGCGCG

## SEQ ID No:5

20 AGACAGGTGGCACCCGTTTTTTTAAATTATTTAATTATATATATATATTATATATATATAY  
ACACACACACACACACACATATATGAGTGTATCTGTCTATCTTTTTAAAAGCATGACC

## SEQ ID No:6

AGACAGGTGGCACCCGTTTTTTTAAATTATTTAATTATATATATATATTATATATATATA(CA)<sub>n</sub>  
25 TATATGAGTGTATCTGTCTATCTTTTTAAAAGCATGACCTACAGACTTAAAACAGCCAAC

## SEQ ID No:7

ATCAGACCCAGCTCCCAAAGTGATGGACTTCAAGGAAAAACCCAGCTCTCCGGCCAAAGGY  
TCGGAAGGTCCTGGGAAAACTGCGTGCCAGTCATCCAGCGGACTTTCGCTCACTCGAGT

-52-

## SEQ ID No:8

ACTGCGTGCCAGTCATCCAGCGGACTTTCGCTCACTCGAGTGGGGAGCAGAGCGGCAGCGR  
CACGGACACAGACAGTGGCTATGGAGGAGAATCGGAGAAGGGCGACTTGCGCAOTGAGCA

## 5 SEQ ID No:9

CTGCAAGATTGTTGCATTGTGTATACTGAGATAATCTGAGGCATGGAGAGCAGATTCAGG(GT),  
ATGTGCGTGTGCGTGACATGTGTGCCTGCGTGTGGTATAGGACTTTAAAGCTCCTTTT

## SEQ ID No:10

10 CTTTAAAGCTCCTTTTGGCATAGGGAAGTCACGAAGGATTGCTTGACATCAGGAGACTTGS  
GGGGGATTGTAGCAGACGTCTGGGCTTTTCCCCACCCAGAGAATAGCCCCCTTCGATACA

## SEQ ID No:11

AAGCTCCTTTTGGCATAGGGAAGTCACGAAGGATTGCTTGACATCAGGAGACTTGGGGGGK  
15 ATTGTAGCAGACGTCTGGGCTTTTCCCCACCCAGAGAATAGCCCCCTTCGATACACATCA

## SEQ ID No:12

TCCTTTTGGCATAGGGAAGTCACGAAGGATTGCTTGACATCAGGAGACTTGGGGGGGATTR  
TAGCAGACGTCTGGGCTTTTCCCCACCCAGAGAATAGCCCCCTTCGATACACATCAGCTG  
20

## SEQ ID No:13

CATAGCACGGTAGTGGTTTGGGGAGGTTTCCGCAGGTCTGCTCCCCACCCCTGCCTCGGAR  
GAATAAAGAGAATGTAGTTCCTACTCAGGCTTTCGTAGTGATTAGCTTACTAAGGAACT

## 25 SEQ ID No:14

CAACGGCATATGGAGTGTCTTATTGCTAAAAAGGATTCCGTCTCCTTCAAAGAAGTTTTW  
TTTTTGGTCCAGAGTACTTGTTCCTGATGTGTCCAGCCAGCTCCGCAGCAGCTTTTCA

-53-

## SEQ ID No:15

TATATAATATATATAAAGGAAAATGTTTCAGATGTTTATTTGTATAATTACTTGATTCTM  
CACAGTGAGAAAAATGAATGTATTCTGTGTTTTGAAGAGAAGAATAATTTTTTTTTTCT

## 5 SEQ ID No:16

TATTTGTATAATTACTTGATTACACAGTGAGAAAAATGAATGTATTCTGTGTTTTGAARAGAAGAATAATTTT  
TTTTTCTCTAGGGAGAGGTACAGTGTTTATATTTTGAGCCTTCC

## SEQ ID No:17

10 GAAGGTGTAAAATTGTAAATATTTTTATCTATGAGTAAATGTTAAGTAGTTGTTTTAAAW  
ACTTAATAAAATAATTCTTTTCTGTGGAAGAGAAAGATGGTCTCCTGAGTTTTTTAA

## SEQ ID NO: 18

MERIPSAQPPFACLPKAPGLEHGDLPGRMYPAHMYQVYKSRRGIKRSEDSKETYKLP  
15 RLIEKKRRDRINECIAQLKDLLPEHLKLTTLGHLEKAVVLELTLKHVKALTNLIDQQQ  
QKIALQSGQLQAGELSGRNVETGQEMFCSGFQTCAREVLQYLAKHENTRDLKSSQLV  
THLHRVVSELLQGGTSRKPSDPAPKVMDFKEKPSSPAKGSEGP GKNCVPVIQRTFAHS  
SGEQSGSDTDTDSGYGGESEKGDLRSEQPCFKSDHGRRFTMGERIGAIIKQSEEPPTK  
KNRMQLSDDEGHFTSSDLISSPFLGPHPHQPPFCLPFYLIPPSATAYLPMLEKCWYPTS  
20 VPVLYPGLNASAAALSSFMNPDKISAPLLMPQRLPSPLPAHPSVDSSVLLQALKPIPL  
NLETKD

## SEQ ID NO: 19

1 ggacaccggg ccatgcacgc ccccaactga agctgcatct caaagccgaa gattccagca  
25 61 gccagggga ttcaaagag ctcagactca gaggaacatc tgcggagaga cccccaagc  
121 cctctccagg gcagtcctca tccagacgct ccgctagtgc agacaggagc gcgcagtggc  
181 cccggctcgc cgcgccatgg agcggatccc cagcgcgcaa ccacccccg cctgcctgcc  
241 caaagcaccg ggactggagc acggagacct accagggatg taccctgccc acatgtacca  
301 agtgtacaag tcaagacggg gaataaagcg gagcgaggac agcaaggaga cctacaatt  
30 361 gccgcaccgg ctcacgaga aaaagagacg tgaccggatt aacgagtga tcgccagct  
421 gaaggatctc ctaccgaac atctcaaact tacaacttg ggtcacttg aaaaagcagt  
481 ggttcttgaa ctaccttga agcatgtgaa agcactaaca aacctaattg atcagcagca  
541 gcagaaaatc attgccctgc agagtgggtt acaagctggg gagctgtcag ggagaaatgt  
601 cgaaacaggt caagagatgt tctgctcagg ttccagaca tgtgccggg aggtgcttca  
35 661 gtatctggcc aagcacgaga acactcggga cctgaagtct tcgcagcttg tcaccacct  
721 ccaccgggtg gtcctggagc tgctgcaggg tggctacctc aggaagccat cagaccagc  
781 tcccaagtg atggacttca aggaanaacc cagctctcc gccaaaggtt cggaaggctc  
841 tgggaaaaac tgcgtgccag tcatccagcg gactttcgt cactcgagtg gggagcagag  
901 cggcagcgac acggacacag acagtggcta tggaggagaa tcggagaagg gcgacttgcg

-54-

961 cagtgcagcag ccgtgcttca aaagtaccca cggacgcagg ttcacgatgg gagaaaggat  
 1021 cggcgcaatt aagcaagagt ccgaagaacc cccacaaaa agaaccgga tgcagctttc  
 1081 ggatgatgaa ggccatttca ctacagtgga cctgatcagc tccccgttcc tgggccca  
 1141 cccacaccag cctccttct gcttgccctt ctacctgac ccaccttcag cgactgccta  
 5 1201 cctgcccattg ctggagaagt gctggatcc cactcagtg ccagtgcctat acccaggcct  
 1261 caacgcctct gccgcagccc tctctagctt catgaaccca gacaagatct cggctccctt  
 1321 gctcatgccc cagagactcc ctctccctt gccagctcat ccgtccgtcg actcttctgt  
 1381 ctgctccaa gctctgaagc caatccccc tttaactta gaaaccaag actaaactct  
 1441 ctaggggatc ctgctgcttt gcttccctc ctgctactt ctaaaaagc acaaaaaag  
 10 1501 ttttgtgaa tgctgcaaga ttgtgcatt ggtatatactg agataatctg aggcattggag  
 1561 agcagattca ggggtgtgt gtgtgtgtgt gtgtgtgtgt gtatgtcgt gtgcgtgcac  
 1621 atgtgtgctt cgtgtgtgt ataggacttt aaagctcctt ttggcatagg gaagtcacga  
 1681 aggatgtctt gacatcagga gacttggggg ggattgtacg agacgtctgg gcttttccc  
 1741 acccagagaa tagcccccct cgatacacat cagctggatt ttcaaaagct tcaagctctt  
 15 1801 ggtctgtgag tcacttcca gtttgggagc tgggtctgtg gctttgatca gaaggtaact  
 1861 tcaaaagagg gcttccagg gctcagctcc caaccagctg ttaggacccc accctttgc  
 1921 cttattgtc gacgtgactc accagacgtc ggggagagag agcagtcaga ccgagcttc  
 1981 tgtaacatg gggaggtagc aggcactggc atagcacggt agtggtttgg ggaggtttc  
 2041 gcaggctgc tccccacccc tgcctcggaa gaataaagag aatgtatct cctactcagg  
 20 2101 ctttctagt gattagctta ctaaggaact gaaaatgggc ccttctaca agctgagctg  
 2161 ccccgaggag agggaggagt tccctgggct tctggcacct gttctaggg ctaaccatta  
 2221 gtacttactg tgcagggaac caaccaaggt tctgagaaat gcggacaccc cgagcgagca  
 2281 ccccaaagtg cacaagctg agtaaaagc tgcctccttc aaacagaact agactcagtt  
 2341 ttcaattcca tctaaact cctttaacc aagcttagct tctcaaggc ctaaccaagc  
 25 2401 cttggcacg ccagatcctt tctgtaggct aattcctctt gccaacggc atatggagt  
 2461 tcttattgc taaaaggat tccgtctct tcaagaagt ttatttttg gtccagagta  
 2521 cttgttttc cgtgtgtcc agccagctcc gcagcagctt tcaagatgc actatgcctg  
 2581 attgtgacg gtgtttaac ttttcttt cctgtttta tttgttatt aagtcgtgc  
 2641 ctttattgt aaagctgta taaatatata ttatataat atattaaaa ggaanaatgt  
 30 2701 tcagatgttt attgtataa ttactgtatt cacacagtga gaaaaatga atgtattcct  
 2761 gttttgaag agaagaataa tttttttc tctagggaga ggtacagtgt ttatatttg  
 2821 gagccttct gaaggtgtaa aattgtaaat attttatct atgagtaaat gtaagtagt  
 2881 tgttttaaa tacttaataa aataattctt ttctgtgga ag

35 SEQ ID NO: 20

1 tagatagtaa cagtatagac tcaatcagca cacagtgtaa ggccaccaag atgtgagtc  
 61 ccaataggaa agaagagaaa gatcccatct ttctttgta cgaaattatg ttcttcccc  
 121 acttagaaga gacaaaacag caggagcggc taaaaatgg caggattacc cagtgcagct  
 181 gctcagtgcc acattgcaca actccagagg gtgctctcac acagactgca atgtgaatag  
 40 241 cttccctgg agttgagcgg tgcacaaccc aaacaacct accaggcaac cgttaagtata  
 301 gtgattaaga gcacaagctt tggagtcaa caaacctggg ggcctgtctc agactgaatc  
 361 ccagactata taacctgggg caggttattt agcctcctg agcctcaatt ttccaaacag  
 421 aatatgttat acatccctag ggcctatttc agtgtctggc attgaataac aataaacacg  
 481 tgcaaatgc atcgagctaa tactagtacc tgcctaaaag gtggtgtgta ggagcaaaga  
 541 aattgacata cgaaaggttt ttaatatcta caaaagatga cagactgaaa tagtaacatt  
 45 601 ctccaggatg gaaagatcta tgccacgtag gaattgttg ttcaattat tatttttaa

661 aagccataag ctatggagag aataacagag tttgtttg tttttaac ctgatacgg  
 721 ggaagctgg taggatgga accgttctg aagcttgaga atacattcgg aacaataaa  
 781 aagtaggaaa tgcatacatt ttgtattta cagtgtagg gcaggtagg gcaaacgta  
 841 ttgataaact caaagaattt taagaatgat attgtcatga gccatgagcc atggaagctg  
 901 caaggtttg gctccctcct gccatcgggt ggggggtgct ggcggaagg ggtacgtgct  
 961 ctgtccctc cagtgctta ttctgtctg gaaccgtggt ttgacgcag ccgtgacagc  
 1021 ccttcacct tattaaaac acacaatgaa gcaggtcgcc caagattgaa agcgcgttc  
 1081 caggcgccgac ccggtcccc gcccttgccc agcaaaagta cattctggca gggagggatc  
 1141 tctgagcccc gaagtgggt catgccagt agcagttaga aaaggaggca ttctcacac  
 1201 ttgctaaaga gttgacgct tgtgaaat aaacaggaag cgggagctct ccaaggcgac  
 1261 ctgaaggaaa tacactgcc gtttggtcaa ctgtgaatg ccagtctct aggtcgtcaa  
 1321 gggcactgcc agttaagact gatccctaa ctgcaccga ggctactact ctccgccag  
 1381 tctcgccagt gacccattt ttttcaat cctccaca gccaggtcac tcagcagtg  
 1441 ggtgactgac ccgaagcgca gtgggaagg cttacagta tcttcaact cccgaact  
 1501 gcaggcgagg ggagcgaga ggtcagtga atccccagcc aggccttatt ttgtcatga  
 1561 gttccactg gctccctcct ctgactgtat cagcgtgct cacaccgag gattggagt  
 1621 tcagctgtt tcctgtctc cggctgagt agaaggtcac agagccgga ctttccggg  
 1681 ggaggtgggt ggggcccccc ggcagcctaa gtgagattgc agagatctgg ggccgctgga  
 1741 ggaggtcct ccgccccggg ctgggggct tgggttagct tctccccgc tctctacct  
 1801 aggcattctg gttacaatga aattaaaaac aaaacacaaa gcaacacaag ttctcattg  
 1861 tttccctc tgtagccag tggcctgat acaatttcc cagggtgccc ttcttatt  
 1921 tctcaattt aaccttcc tagaggtct gcaagtcaa gggcaggatc cgtgtcggat  
 1981 tcatcaacta gtgcagcgcc tagcgagag cagggggctc aagaataacg tctgaccgc  
 2041 atgattgcta agatttccct gtaacaggcg gttttttt ctgtctctc tcatccctc  
 2101 tgccctgggt gcagaccgcg aacagcgccg ccgaacttcc caacaggcag ggagagggcc  
 2161 gatccgggt ggcacgccac gtccccggg tctcagtcct tgggtcaacg cagagaggct  
 2221 cgcggtccgc ggtgtacga cctgagccc gccacgtgaa gcgtcacgcc ctgcgtgct  
 2281 gcaggcgagg cgcgcgccg cgggttgtg aacgtgcag ccgagggga ggcgaccggg  
 2341 gcgctctgc tccggagggg gcagaggagg gagggagcgc cgggcacagc gcccggtatc  
 2401 ttctgctg ttagtgccg ggaggaagg ggtgacctg gggcaccag ggggtctgcg  
 2461 aaccgggtgc ccgcccgcc gcaggtgtg ccagggagcg gagctcctgg gagcagggg  
 2521 cctcggctc acacctcca cggtcagggt cgcgcggcg gctcggcgc agcctcagct  
 2581 gccctgctc ttggcctgc gcccgctcc catgggtga catcgcccc gccctcgg  
 2641 cctcccaa ggcgggcaat tctggacgc gaggtgagc agtgggggca gggaagccag  
 2701 gacgaaaaga aaccacagc tctggggaag gctggggggc cggcgactc cctccgagc  
 2761 gcgccggtc ctcaagcgg gccggcggg ggaggaggaa gagggctggg ctggagctag  
 2821 caaggggata ttcttccc ggcttgatc agacggggc ggtccgctc tccccgtc  
 2881 cctccagga gacgggaact tacttattt cctggggga ggttcgcca cgttacaac  
 2941 ttctcccc cccacagc cccgtccct tccagctcc gcgccccca cccaactggg  
 3001 caggaccag gtcgtgctc cccccctt tggggaaag gcggcgag ccgcagacac  
 3061 ctgggggccc gggctggggg tgggggctc ctgacagcg ccggagcgtt gtccaacacg  
 3121 tgagactcat gtgatgaag cgggggagg cgggcaggtc gctcctccc tccccggag  
 3181 tggccagag tgcctggagt cacagggtag aacacgtag tccaaccac cactcgtc  
 3241 ccatttaacc cagccgcag cctctcatt actctcgge ttcccccc accccccac  
 3301 tccgcctaa ccgcccccc ctcaccgct cctcccgcc tccccccg cccacttct  
 3361 cattcactg gctcgcacg cgcagacaga ccgcgcagg agcacacac gccagctgt  
 3421 gcgctgagtc ggagccagag gcccgggga caccgggcca tgcacgccc caactgaagc  
 3481 tgcattcaca agccgaagat tccagcagc caggggattt caaagagtc agactcagag



3541 gaacatctgc ggagagaccc ccgaagccct ctccagggca gtctcatcc agacgtccg  
 3601 ctagtgcaga caggagcgcg cagtggcccc ggctcgccgc gccatggagc ggatccccag  
 3661 cgcgcaacca cccccgcct gcctgcccac agcaccggga ctggagcacg gagacctacc  
 3721 agggtaagtt ggcactcctt ggccctcaa gcctcaactg cagccccatg ttatgcgcca  
 5 3781 ctctcaactt ggagcagcic cgggcgcacc gggagggtct tgcgggcag aacgcctgca  
 3841 gccgtgcgca agcagtcacg acccttcctg gtctctctc ctgcaggatg taccctgccc  
 3901 acatgtacca agtgtacaag tcaagacggg gaataaagcg gagcgaggac agcaaggtaa  
 3961 gcaagtgcac ccctagggac cctgcgctca gcccctcgcg cgcgctgagt ttccaagaaa  
 4021 agttttctcg ctttgagggt ggcgagggga tgcagggtgt gggctcggtg cctctctga  
 10 4081 gtgacttgga aaagaaaggg cagacgatgg ttctgggtgc tactctgcta ctctgtcct  
 4141 ctgccggact gttgctgcgg ggctgggagg ataggcttct catctcttc cccaagcgcc  
 4201 caccgcctcc ccgtcgctct tgcaggagac ctacaaatg ccgcaccggc tcatcgagaa  
 4261 aaagagacgt gaccggatta acgagtgcac cgcccagctg aaggatctcc taccgaaca  
 4321 tctcaaactt acagtaagt agaagctggc ccttttcaa ccagtcctt tgcccagagg  
 15 4381 gcggggcgggt cactcgccgc ctgcagggtc cgcggggaac tgcagaccag actggcggat  
 4441 cagagctggc ggggtggctct gcggtgggggt cctctccac agtctggcg ttttctggt  
 4501 gactcatgca aatgaggcga gaaccacttg gaccttcca agttggtcc aacaccaact  
 4561 ggccttcctt ttcaggagt taactctgg tgatttcag gattccctag ttttctcac  
 4621 ttaaaggaac acgccaagaa acacacacat ttatttacc cctccccctc taccactccc  
 20 4681 cccacctttt ttgtgtgtg tgcataataa ggggacttgc ttgtgtgtg gatttttacg  
 4741 gcctgtcctt tctgacagt agccctcggc tacttcgag cctttggtg gggaaatgga  
 4801 aaaaaaaaa atagtatttc gggaggaaca aaaaagcctg gatgagctgg aagttctgaa  
 4861 aggggtgaag gaaagaagta gggaaagcct ctgggtgcc agacgtaata gaggtccctc  
 4921 tctgagttga caccactgca ggaaaatgt atctctggat tccctgagt taaggctggc  
 25 4981 agaggctgct ggagaaattt atctgtcaaa ggatttcct gaggtagtig cagcttcaa  
 5041 aatgcctcca aagacagggt gcacccgttt ttttaatta tttaattata tatatatatt  
 5101 atatatatat atacacacac acacacacac acatatatga gtgtatctgt ctatctttt  
 5161 aaaagcatga cctacagact taaaacagcc aaccaggaaa cactattcca cttttttt  
 5221 tcttttca tttctattg ctaataaatg tccaaagggt gggacttctc tgacctacc  
 30 5281 gctgactaag gctctttcc ttccagactt tgggtcactt ggaaaaagca gtggttcttg  
 5341 aacttacctt gaagcatgtg aaagcactaa caaacctaat tgatcagcag cagcagaaaa  
 5401 tcatgcccct gcagagtggg ttacaagctg gtgagtgtg attctggcta tgcctctt  
 5461 aagagtttga gtgcaaatag agagcccgtg ggctcaacat ctgatgtaat aaacattact  
 5521 gcaacaaatt gcttatgcac gticattggg ggagatgcag tttatctt cctaaaagg  
 35 5581 cagacttttc attgaaatg cattgtgcca cctggcatga atacgtatta gtgaaatgat  
 5641 aagatatccc tgtggcattt tagcttgaga gtctctgggt tctgggagat ttccctactc  
 5701 ccttttaaaa tgccaaggca cctataattt gcaattgggg tgtttacag ttggtcttct  
 5761 tagccctctt tcatggaga agaaatcatg ggtatgcccc agcgttttcc tgtttcttg  
 5821 cttcctgtc acttggtgtg tgggtgtatc ctggcaggat acagcaggag ttttctctg  
 40 5881 attcatgtg gticcctgaa tagccactag gtatcttggg gaattgcaca atctagcgaa  
 5941 accactgaag ttcatcattt cgttttact gacttccaga taatcgaggt caaccttcta  
 6001 accttctagt ctacttctt ccaaataata ctgtacagac tggggagaat tattctacc  
 6061 actccctcat ttcatgctg tctgccttcc tctgaaggc tctgtatgat aaaattgcaa  
 6121 aaaccagct agtgcttctg cctgtttcct cattcaaat aggaagatgg tcatacctaa  
 45 6181 tgtcttgagg atcatggata gaatatgtgg agaagacata gaaatagcct aattaagggt  
 6241 cacagcatga ctgcaacttt tacaatcat tgaataaag ttactttag gtgattgttg  
 6301 ttttctcatt cttttctca tttataact atccagcctc tgccatttt gccacgggtc  
 6361 aatgttgtat gcattgactc ttaggttat aaatacatca gaatttctt tctgcctcg

6421 cttacatgga aaactcacia accacctata caatccaaaa gaggggaaac agctcatctc  
 6481 atattaatta tgggccattt ccatgatagg atattatgca accattaaaa atcataittt  
 6541 atctgagtgt tagtatatgg attattttaa ttatttatac ttttcagtgt aattcttctc  
 6601 tgagcatact acttttggag ttaggaaacac aaatcagtaa atgcattttt ttttttaac  
 5 6661 aaaaactaaa gcacctgggt ttttggagta tagtttccag gtgcgccaca ggccttctga  
 6721 aacgttttcc ttcggatttt tctttcccca ggtgagctgt caggagaaaa tgcgaaaca  
 6781 ggtcaagaga tgttctgctc aggtttccag acatgtgccc gggaggtgtc tcatgtctg  
 6841 gccaaagcag agaacactcg ggacctgaag tcttcgcagc ttgtaccca cctccaccgg  
 6901 gtgtctcgg agctgctgca ggggtgtacc tccaggaagc catcagaccc agctcccaaa  
 10 6961 gtgatggact tcaaggaaaa acccagctct cgggcaaaag gttcggaagg tcttgggaaa  
 7021 aactgctgca cagtcacca ggcgacttcc gctactcga gtggggagca gagcggcagc  
 7081 gacacggaca cagacagtgg ctatggagga gaatcggaga agggcgactt gcgcagtga  
 7141 cagccgtgct tcaaaagtga ccacggacgc aggttcacga tgggagaaag gatcggcgca  
 7201 attaaagcaag agtcggaaga acccccccaca aaaaagaacc ggatgcagct ttcggaatg  
 15 7261 gaaggccatt tcaactagcag tgacctgac agctccccgt tcttgggccc acaccacac  
 7321 cagcctcctt tctgctgcc ctctacctg atccacatt cagcgactgc ctacctgcc  
 7381 atgtggaga agtgcgtgta tcccactca gtgccagtgc tataccagg cctcaacgcc  
 7441 tctgccgag cctctctag ctctatgaac ccagacaaga tctcgctcc ctgtctatg  
 7501 cccagagac tcccttctc ctgccagct catccgtccg tgcacttcc tgttctgctc  
 20 7561 caagctctga agccaatccc cctttaaac ttgaaacca aagactaaac tcttagggg  
 7621 atcctgtgc ttgtttcc ttcctgcta ctcttaaaa agcaaaaaa aagttttgt  
 7681 gaatgtgca agattgtgc attgtgata ctgagataat ctgaggcatg gagagcagat  
 7741 tcagggtgtg tgtgtgtg tgtgtgtg tgtgtatgt cgtgtgctg cacatgtgtg  
 7801 cctgcgtgtt ggtataggac tttaaagctc cttttggcat agggagtc cgaaggattg  
 25 7861 ctgacatca ggagacttg gggggattgt agcagacgc tgggctttc cccaccaga  
 7921 gaatagcccc ctctgataca catcagctgg atttcaaaa gcttcaaat ctggctgt  
 7981 gactcactct tcatgttgg agctgggtct gtggcttga tcagaaggta cttcaaaag  
 8041 agggcttcc agggctcagc tcccaaccag ctgttaggac cccaccttt tgccttatt  
 8101 gtgcagtgta ctaccagac gtccgggaga gagagcagtc agaccagct tctgctaac  
 30 8161 atggggaggt agcaggcact ggcatagcac ggtagtgtt tggggaggt tccgcaggtc  
 8221 tctccccac cctgcctcg gaagaataaa gagaatgtag ttccctactc aggtttctg  
 8281 agtgattagc ttactaagga actgaaatg ggcccctgt acaagctgag ctgccccga  
 8341 gggaggagg agttccctgg gttctggca cctgttcta ggcctaacca ttagtacta  
 8401 ctgtgcaggg aaccaaaacca aggtctgaga aatgcggaca cccgagcga gcaccccaaa  
 35 8461 gtgcacaaag ctgagtaaaa agctgcccc ttcaaacaga actagactca gtttcaatt  
 8521 ccatcctaaa actccttta accaagctta gtttcaaaa ggcctaacca agccttggca  
 8581 ccgccagatc ctctcttag gctaattct ctgcccac ggcataatga gtgtcttat  
 8641 tgctaaaaag gattccgtct cttcaaaaga agttttatt ttggtccaga gtactgttt  
 8701 tccgatgtg tccagccagc tccgcagcag ctttcaara tgcactatgc ctgattgctg  
 40 8761 atcgtgttt aacttttct ttcctgtt ttatttgg attaaagctg tgccttatt  
 8821 tgtaagctg ttataaatat atattatata aatatattaa aaaggaaaat gttcagatg  
 8881 ttatttga taattactg attcacacag tgagaaaaa tgaatgtatt cctgttttg  
 8941 aagagaagaa taattttt ttctctagg gagaggtaca gtgttatat ttggagcct  
 9001 tctgaaggt gtaaaattgt aaatatttt atctatgagt aaatgttaag tagttgttt  
 45 9061 aaaatactta ataaaataat tctttctg tgggaagaga agatggctc ctgagtttt  
 9121 taaaatagct cacttgggtg gatattgctg actccatgt cctcttct tggctgaagc  
 9181 aaaccagtta atctcagtgt aatttattc agctttcat gtgcttga ttcaatcaga  
 9241 ataagcttag tcaacctggc aggtaaatat tggttcaatt ttgtttaac ccttgcagg

[illegible]

9301 gggtcatgat catcctctac ctctttccag agttaagtaa aaagcatatt ttcccttgcc

**9361 ctgctttcat cg**

THE UNIVERSITY OF CHICAGO

[illegible]

**Figure 1**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**